# CSRM617 hydrochloride

**Cat. No.:** HY-122611A

**CAS No.:** 1353749-74-2

**Molecular Formula:** $C_{10}H_{14}ClN_3O_5$

**Molecular Weight:** 291.69

**Target:** Androgen Receptor; Apoptosis

**Pathway:** Vitamin D Related/Nuclear Receptor; Apoptosis

**Storage:** -20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)




## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 125 mg/mL (428.54 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 3.4283 mL | 17.1415 mL | 34.2830 mL |
| | 5 mM | 0.6857 mL | 3.4283 mL | 6.8566 mL |
| | 10 mM | 0.3428 mL | 1.7141 mL | 3.4283 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

CSRM617 hydrochloride is a selective small-molecule inhibitor of the transcription factor ONECUT2 (OC2, a master regulator of androgen receptor) with a $K_d$ of 7.43 uM in SPR assays, binding to OC2-HOX domain directly. CSRM617 hydrochloride induces apoptosis by appearance of cleaved Caspase-3 and PARP. CSRM617 hydrochloride is well tolerated in the prostate cancer mouse model[1]

**In Vitro**

CSRM617 (0.01-100 μM; 48 hours) hydrochloride inhibits cell growth in several PC cell lines: PC-3, 22RV1, LNCaP, C4-2 cells[1].
CSRM617 (10-20 μM; 48 hours) hydrochloride induces apoptosis in 22Rv1 cells results in cell death in a concentration-dependent fashion[1].
CSRM617 (20 μM; 72 hours) hydrochloride induces apoptosis in 22Rv1 cells by appearance of cleaved Caspase-3 and PARP[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**

CSRM617 (50 mg/kg; p.o.; daily, for 20 d) inhibits tumor growth in SCID mice with 22Rv1 xenograft[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| | |
|---|---|
| Animal Model: | SCID mice with 22Rv1 xenograft[1] |

| | |
|---|---|
| Dosage: | 50 mg/kg |
| Administration: | Oral administration; daily, for 20 days |
| Result: | Elicited a significant reduction in the onset and growth of diffuse metastases. |

## CUSTOMER VALIDATION

- Cancers (Basel). 2023 Jun 27, 15(13), 3375.

See more customer validations on www.MedChemExpress.com

## REFERENCES

[1]. Rotinen M, et, al. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nat Med. 2018 Dec;24(12):1887-1898.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA